| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
51,330,000 |
| Market
Cap: |
11.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2235 - $0.2235 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. Co.'s product candidate, FMX114, which is being evaluated for the potential treatment of mild-to-moderate atopic dermatitis. Co. is also in the preclinical stages of developing products containing Bromodomain and Extra-Terminal Domain (BET) inhibitor compounds. Co.'s initial BET inhibitor candidate in development is VYN201, an administered pan-BET inhibitor, which it is exploring in various immuno-inflammatory diseases, including skin diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
13,000 |
43,000 |
| Total Buy Value |
$0 |
$0 |
$50,778 |
$125,458 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
1 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Zeronda Tyler |
Interim CFO |
• – – |
2021-06-30 |
4 |
D |
$3.51 |
$2,457 |
D/D |
(700) |
22,695 |
|
- |
|
| Zeronda Tyler |
Interim CFOOfficer |
• – – |
2021-06-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
23,395 |
|
-63% |
|
| Saik Andrew |
Chief Financial Officer |
• – – |
2021-05-28 |
4 |
A |
$3.36 |
$10,130 |
D/D |
3,017 |
116,468 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2021-05-28 |
4 |
A |
$3.36 |
$3,159 |
D/D |
941 |
474,458 |
|
- |
|
| Lepore Patrick G |
Director |
– • – |
2021-05-26 |
4 |
B |
$3.60 |
$44,958 |
D/D |
12,500 |
37,500 |
2.39 |
-65% |
|
| Edelman Joseph |
10% Owner |
– – • |
2021-05-06 |
4 |
S |
$3.67 |
$3,670,000 |
I/I |
(1,000,000) |
5,773,954 |
|
58% |
|
| Domzalski David |
President and CEO |
• • – |
2021-03-31 |
4 |
D |
$6.84 |
$43,201 |
D/D |
(6,316) |
473,517 |
|
- |
|
| Wiley Matthew T. |
Chief Commercial Officer |
• – – |
2021-03-31 |
4 |
D |
$6.84 |
$17,599 |
D/D |
(2,573) |
114,397 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2021-03-31 |
4 |
D |
$6.84 |
$13,304 |
D/D |
(1,945) |
98,833 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2021-03-31 |
4 |
D |
$6.84 |
$12,073 |
D/D |
(1,765) |
108,873 |
|
- |
|
| Saik Andrew |
Chief Financial Officer |
• – – |
2021-03-31 |
4 |
D |
$6.84 |
$5,212 |
D/D |
(762) |
113,451 |
|
- |
|
| Lepore Patrick G |
Director |
– • – |
2021-03-15 |
4 |
B |
$7.41 |
$92,563 |
D/D |
12,500 |
25,000 |
2.39 |
-63% |
|
| Domzalski David |
President and CEO |
• • – |
2021-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
153,750 |
479,833 |
|
- |
|
| Saik Andrew |
Chief Financial Officer |
• – – |
2021-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
29,213 |
114,213 |
|
- |
|
| Wiley Matthew T. |
Chief Commercial Officer |
• – – |
2021-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
27,675 |
116,970 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2021-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
29,213 |
110,638 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2021-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
29,213 |
100,778 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2021-01-28 |
4 |
B |
$2.37 |
$9,999,999 |
I/I |
4,219,409 |
27,095,819 |
1.5 |
-54% |
|
| Wiley Matthew T. |
Chief Commercial Officer |
• – – |
2020-12-31 |
4 |
D |
$1.58 |
$2,435 |
D/D |
(1,541) |
357,181 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2020-12-31 |
4 |
D |
$1.58 |
$15,256 |
D/D |
(9,656) |
1,304,334 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2020-12-31 |
4 |
D |
$1.58 |
$2,879 |
D/D |
(1,822) |
325,703 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2020-12-31 |
4 |
D |
$1.58 |
$3,757 |
D/D |
(2,378) |
286,262 |
|
- |
|
| Lepore Patrick G |
Director |
– • – |
2020-12-03 |
4 |
AB |
$1.71 |
$85,425 |
D/D |
50,000 |
50,000 |
|
-19% |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2020-11-30 |
4 |
A |
$1.45 |
$15,115 |
D/D |
10,460 |
327,525 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2020-11-30 |
4 |
A |
$1.45 |
$6,160 |
D/D |
4,263 |
1,313,990 |
|
- |
|
165 Records found
|
|
Page 4 of 7 |
|
|
